{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-002001","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.340487+00:00","generated_at":"2026-05-24T01:08:48.440892+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO","bullets":["Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.","Phase 2 THIO-101 expansion underway; potential accelerated approval filing in 2026.","Phase 3 THIO-104 set to begin mid-2025; potential full approval filing in 2026.","Multiple THIO trials planned in additional cancer indications.","Significant market opportunity in hard-to-treat cancers with unmet medical needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-002001","json":"https://secwatch.observer/filing/0001641172-25-002001.json","markdown":"https://secwatch.observer/filing/0001641172-25-002001.md","text":"https://secwatch.observer/filing/0001641172-25-002001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/0001641172-25-002001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:08:48.440892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}